Along this line, dipeptidyl peptidase-4 (DPP-4) inhibitors were developed to stabilize endogenous GLP-1, an approach which is effective in treating obesity and diabetes [2]. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.